OP-ED: FUNDING ROADBLOCKS CREATING DIGITAL HEALTH INEQUITY Beyond just clinical: Making the case for a pivot in reimbursement by Australian Government
With
Helen Souris,
CEO and Executive Director
Cardihab &
Board Member
Medical Technology Association of Australia (MTAA)
OP ED SEGMENT
Filmed in Sydney | June 2026
Helen Souris, CEO and Executive Director of Cardihab and Chair of the Digital Health Advisory Group at the Medical Technology Association of Australia (MTAA), highlights the significant gap in cardiac rehabilitation access across Australia. Despite the proven benefits of cardiac rehabilitation in improving survival, quality of life, and reducing hospital admissions, around 80% of eligible patients do not receive this care, with access rates even lower in regional and rural communities.
Cardihab was established as a digital health company originating from CSIRO research and has spent the past decade developing a digital therapeutic solution for cardiac rehabilitation.
Delivered through a clinically supervised software platform, the program enables patients to access rehabilitation remotely, removing barriers associated with travel and face-to-face attendance. The platform is registered with the Therapeutic Goods Administration (TGA) as a Class IIa medical device, reflecting its compliance with rigorous clinical and regulatory standards.
Over ten years, Cardihab has built a substantial evidence base, including randomised controlled trials and real-world studies. Independent research has demonstrated improvements in patient outcomes, quality of life, and cost-effectiveness, with the program outperforming traditional alternatives in most evaluated scenarios. As a result, the majority of private health insurers now support access to the platform, while statewide implementation has been achieved through partnerships such as the Tasmanian Health Service.
Despite these successes, Souris identifies funding as the primary barrier to broader adoption within the public health system. She argues that Australia already possesses the technology required to support the government’s digital health ambitions and that sustainable funding and reimbursement mechanisms are now needed to enable widespread access to evidence-based digital therapeutics and remote patient care solutions.
Source: Adapted from transcript
Media access credit: Medical Technology Association of Australia (MTAA)
Note: Op Ed segments are opinions and comments on policies. They should be watched for awareness purposes only, and do not necessarily reflect the views held by Australian Health Journal.
-
Lens on patient care & allied health workforce across settings
The CEO of Allied Health Professions Australia (AHPA), Bronwyn Morris-Donovan spoke with Australian Health Journal about the following:
The structure and priorities for AHPA
The setting and disciplines in Allied Health
Allied Health representation in the Strengthening Medicare Task Force
Importance of a data strategy and interoperability in delivery of allied health services
Key allied health priorities hopefully addressed in Federal Budget.In the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
Care workforce challenges
In a wide ranging report looking at the carer needs across Australia, PwC Australia published Reimagine Care Workforce Solutions in October 2022.
Australian Health Journal spoke with Kerryn Dillon, Director Ageing and Reablement and Health Workforce at PwC Australia about the community care sectors of aged care, disability care and childcare the report covers.
-
New option for management of high-risk soft tissue sarcoma of the limb
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
